ToolsCalculators
GALAD Model for Hepatocellular Carcinoma (HCC)
GALAD Model for Hepatocellular Carcinoma (HCC)
Age
years
Sex
AFP (alpha-fetoprotein)
ng/mL
AFP-L3 fraction
%
DCP (PIVKA-II)
mAU/mL
Complete the fields above to see the result.
When to use
- Estimating pretest likelihood of HCC in patients with chronic liver disease using age, sex, AFP, AFP-L3, and DCP.
- Surveillance adjunct alongside imaging in cirrhosis or chronic viral hepatitis.
Formula
Z = -10.08 + (0.09 x age) + (1.67 x sex [male=1, female=0]) + (2.34 x log10 AFP) + (0.04 x log10 AFP-L3%) + (1.33 x log10 DCP). Probability = e^Z / (1 + e^Z).
Pearls and pitfalls
- Developed and validated using the Wako/Eisai DCP (PIVKA-II) assay; results are assay-dependent.
- Performs well for early-stage HCC detection compared with AFP alone.